The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Honeywell International Inc. engages in the aerospace technologies, building automation, energy and sustainable solutions, and industrial automation businesses in the United States, Europe, and ...

1 Day VRTX -0.71% DJIA 0.38% S&P 500 0.53% Health Care/Life Sciences 0.19% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Factory automation Sensor market Size & Growth Report Driven by industry 4.0, IoT integration, and the demand for smarter manufacturing, efficiency and automation are enhanced across various ...

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals’ (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid ...

Rights May 27, 1996 Jun 18, 1996 Sep 21, 1996 Rights ratio: 1 share for every 4 held at a price of Rs 70.0 Rights Feb 05, 1993 Mar 01, 1993 Sep 30, 1993 Rights ratio: 2 share for every 5 held at a ...